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Abstract Immediate type allergic reactions to medication
are potentially life threatening and can hamper drug therapy
of several medical conditions. Exact incidence and preva-
lence data for these reactions in children are lacking. If no
alternative drug treatment is available, a desensitization
procedure may secure the continuation of necessary
therapy. Desensitization is only appropriate in case of a
strong suspicion of an IgE-mediated allergic reaction. It
should be performed by trained clinicians (allergy special-
ists) in a hospital setting where treatment of a potential
anaphylactic reaction can be done without any delay. In this
article, literature describing desensitization procedures for
several antibiotics, antineoplastic agents, and vaccines in
children is reviewed. In general, desensitization schemes
for children differ only in final dose from schemes for
adults. Contradictory data were found regarding the
protective effects of premedication with antihistamines
and glucocorticoids.
Keywords Children.Drug allergy.Prevalence.
Desensitization.Protocol
Introduction and definitions
A drug allergy is an adverse drug reaction that results from
a specific immunologic response to a medication. Allergic
drug reactions account for about 6–10% of all adverse drug
reactions, but up to 10% of fatal reactions in the adult
population [17]. There are no prevalence data or incidence
data for children regarding these allergic drug reactions.
The World Allergy Organization (WAO) has recommen-
ded dividing immunologic drug reactions into immediate
type I reactions (onset within1ho fe x p osure) and delayed
reactions (onset after 1 h), based upon the timing of the
appearance of symptoms [10]. The signs and symptoms of
type I reactions are directly attributable to the vasoactive
mediators released by mast cells and basophils. The most
common signs and symptoms are urticaria, pruritus,
flushing, angioedema (sometimes leading to throat tightness
with stridor), wheezing, gastrointestinal symptoms, and
hypotension. Anaphylaxis is the most severe presentation of
an IgE-mediated drug reaction.
The drugs most commonly implicated in type I reactions
in children are beta-lactam drugs, i.e., penicillins and
cephalosporins.
Diagnostic procedures in drug allergy are confined to a
detailed clinical history and confirmation of an IgE-
mediated reaction. The ENDA (European Network for
Drug Allergy, an interest group of the EAACI) has set up
guidelines on how to perform these tests [4]. In drug
allergy, skin tests and in vitro laboratory tests are
cumbersome, because the test reagents are not standardized
and may even be harmful for a patient with a severe drug
reaction. For this reason, the guidelines provide practical
skin test methods, test concentrations, and selection of
patients. The drug provocation test, the controlled admin-
istration of the suspected drug is considered to be the gold
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1306 Eur J Pediatr (2010) 169:1305–1309standard in order to confirm the diagnosis drug allergy
[ENDA, 1].
Desensitization can be considered in patients who are
proven (by positive skin testing or in vitro tests) or are
strongly suspected to have an IgE-mediated drug allergy and
for whom there are no acceptable alternate drugs (see
“Practical proposal”).In patientswith (multi)resistant bacteria
or patients with multiple drug allergies the effect of a
desensitization procedure (successful treatment) may out-
weigh the risks. Desensitization is a procedure which alters
the immune response to the drug and results in temporary
tolerance, allowing the patient with IgE-mediated allergy to
receive a subsequent course of the medication safely.
Desensitization should not be attempted in patients with
histories of non-IgE-mediated reactions such as Stevens–
Johnsonsyndromeortoxicepidermalnecrolysisbecauseeven
small doses of the drug may induce severe progressive
reactions. Desensitization is also not appropriate for patients
with type III (IgG-mediated) hypersensitivity drug reactions
like hemolytic anemia or nephritis.
Drug desensitization should only be performed by clini-
cians trained in the technique (usually allergy specialists), in a
hospitalsetting(oroutpatientsettingundercloseobservation),
with intravenous access and necessary medications and
equipment to treat anaphylaxis. Pharmacy staff may be
consulted prior to the procedure to assist with preparation of
the required drug dilutions. Articles concerning protocols are
scarce and involve primarily adult patients. In this review, we
summarize the known literature concerning pediatric patients
who underwent a desensitization procedure.
Review of the literature
For studies describing desensitization procedures in chil-
dren, PubMed was searched using the combination of
keywords “desensitization”, “drug hypersensitivity or drug
allergy”, and “child”. The articles found were reviewed for
relevance and references were searched where appropriate.
Most articles are case reports. Some studies describe case
series of adult patients and include one or more children.
Very few studies confined to children only were found. This
review is limited to desensitization procedures with anti-
biotics, beta-lactam drugs [8, 22, 23], co-trimoxazole [12,
13, 20], ciprofloxacin [2, 9, 15], cytostatics, carboplatin [5,
14, 18, 19], L-asparaginase [21], and MMR-vaccine [16]i n
children only.
Procedures
In general, protocols for children differ from those for
adults only in the final dose, which should be the daily dose
used for adequate therapy.
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are:
– Starting doses range from 10% to 0.00001% of the
therapeutic dose (mean 0.001%)
– Administration route orally or intravenously
– Time interval between two gifts range from 15 to
120 min (mean 30 min)
– Total duration of desensitization range from 2 h to
21 days (mean 6 h)
– Increment step range from two times to ten times
(mean three times)
Whether premedication with corticosteroids and antihist-
amines reduces the risk of a desensitization procedure is not
known.
Antibiotics
Desensitization procedures are reported to be successful in
children with symptoms of an IgE-mediated hypersensi-
tivity reaction like urticaria, angioedema, itch, or anaphy-
laxis. If reliable skin test procedures are available, such as
for beta-lactam antibiotics, these should be performed
first. Negative results to intradermal tests with penicilloyl-
poly-L-lysine and minor determinant mixture reduce the
risk of hypersensitivity symptoms upon re-exposure to less
than 5%. In these patients, incremental dosing may be
chosen, however, studies comparing this strategy to
desensitization with regard to safety and efficacy have not
been published.
The starting dose for intravenous procedures is generally
1/1,000,000–1/1,000 of full therapeutic dose, but may be
higher (1/100) in oral desensitization [2, 8, 9, 12, 13, 15,
20, 22, 23]. During intravenous desensitization the doses
are infused continuously over 15–30 min intervals, fol-
lowed by intravenous administration of the full therapeutic
doses. In the oral procedure, dose intervals described range
from 15 min (for ciprofloxacin [15]) to 12 h (for co-
trimoxazole [12]). Slow or incomplete absorption from the
gastrointestinal tract should be taken into account when
choosing this dose interval.
Cytostatics
As cytostatics are usually dosed per square meter, the full
therapeutic dose is different for every child. Intravenous
desensitization with carboplatin starts at a dose of 0.01–
1 mg, infused over 1 min (0.01–1 mg/min). Dose incre-
ments are made every 15 min by prolonging the infusion
time holding the infusion rate constant. When 15–22.5 mg
in 15–22.5 min is well tolerated, the infusion rate is
increased to 100 mg/h for 1 h followed by 200 mg/h for the
remainder of the dose [5, 18, 19].
L-Asparaginase is administered intramuscularly, but
intravenous desensitization had been described starting at
a 1 IU dose, doubled every 10 min [21].
Intravenous desensitization for methrotrexate is started at
1/1,000 of the full dose in 1.5 h followed by 1/100 in 1.5 h,
1 / 1 0i n6ha n dt h er e m a i n i n gd o s ei n2 4he v e r y
therapeutic cycle [3, 7]. This procedure may necessitate a
dose reduction due to increased toxicity as a result of
prolonged exposure to methotrexate [3].
Vaccines
Desensitization to MMR-vaccine is performed by subse-
quent sc administration of 0.05 ml of a 1/100 dilution,
0.05 ml of a 1/10 dilution, and 0.05 ml of the full strength
vaccine up to the 0.5-ml dose [16].
Premedication
Premedication can be done with (methyl)prednisolone,
antihistamine, and ranitidine with or without montelukast
13, 7, and 1 h, respectively, before start of the
desensitization procedure [18, 19, 21] but the protective
effects have not been systematically studied. Administra-
tion of a full therapeutic dose in combination with
premedication, as an alternative to desensitization, resulted
in severe hypersensitivity reactions in three of eight
patients reacting to E. coli asparaginase [21]. A recent
study in children with carboplatin hypersensitivity reac-
t i o n ss u g g e s t st h a ta d m i n i s t r ating a full dose in combina-
tion with premedication may be as effective as
desensitization without premedication [14]. However, due
to its retrospective nature, it cannot be ruled out that
desensitization was preferably initiated in children with
more severe hypersensitivity reactions.
Symptoms
In almost 50% of the procedures reviewed in this article,
symptoms did occur during the procedure. In general, the
symptoms could be treated by antihistamines and dose
reduction or postponing dose increase [5, 12, 22, 23].
Effectivity
Success rates in the reports described (mostly IgE-
mediated allergy) range from 50% to 100% (see Table 1
for details). However, due to the low number of cases
reported and lack of comparative prospective studies,
success rate may be either lower or higher in reality.
Larger case series in adult patients report a success rate of
m o r et h a n9 0 %i nb o t ha l l ergy to antibiotics and to
cytostatics.
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Desensitization in a child with drug allergy should be done
by experienced staff with all facilities to treat medical
emergencies.
Practical proposal
Is an alternative, non-
cross-reactive drug 
available?
Use alternative drug yes
no
IgE-mediated 
hypersensitivity?
Skin tests possible? 
(available; patient stable; 
no antihistamines used; 
no time pressure)
Consider graded challenge
if not contra-indicated
no
yes
no
Desensitization or graded 
challenge if not contra-
indicated
yes
positive
Skin test negative Desensitization or graded 
challenge if not contra-
indicated
Desensitization if not 
contra-indicated
This flowchart is used to decide if desensitization or
graded challenge (adapted from Turvey et al. [23]) should
be employed.
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